Adverum Biotechnologies, Inc.
DelistedCIK 1501756fmd_0F9BMSK0HSPM9GPWN25FM6VF14Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2012 to Sep 30, 2025, 52 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 | – | 2 | 2 | 0 | 0 | 8 | 0 | 4 | 1 |
| Cost of revenue | – | – | 1 | 0 | – | – | – | – | – | – |
| Gross profit | – | – | 1 | 2 | – | – | – | – | – | – |
| Research and development | 25 | 32 | 40 | 50 | 40 | 73 | 89 | 99 | 77 | 77 |
| Total operating expenses | 50 | 117 | 61 | 80 | 69 | 118 | 154 | 157 | 133 | 140 |
| Operating income | (48) | (115) | (59) | (78) | (69) | (118) | (146) | (157) | (129) | (139) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 0 | 1 | 3 | 4 | 4 | 2 | 1 | 3 | 6 | 8 |
| Income before taxes | (47) | (115) | (56) | (74) | (64) | (116) | (146) | (154) | (123) | (131) |
| Income tax expense | 0 | (1) | 0 | (1) | 0 | 1 | 0 | 0 | (1) | 0 |
| Net income from continuing operations | (47) | (114) | (56) | (73) | (64) | (118) | (146) | (155) | (122) | (131) |
| Net income | (47) | (114) | (56) | (73) | (64) | (118) | (146) | (155) | (122) | (131) |
| Net income to common shareholders | (47) | (114) | (56) | – | – | – | – | – | – | – |